Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical (LFCR) Debt to Equity: 2010-2025

Historic Debt to Equity for Lifecore Biomedical (LFCR) over the last 14 years, with May 2025 value amounting to $90.72.

  • Lifecore Biomedical's Debt to Equity rose 910.38% to $90.72 in Q2 2025 from the same period last year, while for May 2025 it was $90.72, marking a year-over-year increase of 910.38%. This contributed to the annual value of $90.72 for FY2025, which is 910.38% up from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical's Debt to Equity is $90.72, which was up 74.83% from $51.89 recorded in Q1 2025.
  • Lifecore Biomedical's Debt to Equity's 5-year high stood at $90.72 during Q2 2025, with a 5-year trough of -$27.00 in Q3 2024.
  • Moreover, its 3-year median value for Debt to Equity was $6.35 (2024), whereas its average is $17.88.
  • The largest annual percentage gain for Lifecore Biomedical's Debt to Equity in the last 5 years was 4,598.17% (2023), contrasted with its biggest fall of 1,894.05% (2023).
  • Lifecore Biomedical's Debt to Equity (Quarterly) stood at $1.07 in 2021, then soared by 30.08% to $1.39 in 2022, then surged by 4,598.17% to $65.35 in 2023, then crashed by 88.98% to $7.20 in 2024, then soared by 910.38% to $90.72 in 2025.
  • Its Debt to Equity stands at $90.72 for Q2 2025, versus $51.89 for Q1 2025 and $7.20 for Q4 2024.